Longeveron presents MRI data on stem cell therapy for Alzheimer's

Longeveron Inc. (NASDAQ: LGVN) presented data from its Phase 2 CLEAR-MIND clinical trial showing that treatment with stem cell therapy laromestrocel was associated with reduced neuroinflammation measured by MRI compared to placebo in patients with mild Alzheimer's disease.

The poster presentation at the Clinical Trials on Alzheimer's Disease Conference examined the effects of laromestrocel on brain inflammation using diffusion tensor imaging and free water analysis. Results showed patients receiving laromestrocel exhibited reduced free water fraction compared with placebo at week 39 in several brain regions, including the hippocampus, temporal cortex, occipital cortex, and parietal cortex.

The hippocampus showed a dose response, with statistical significance in two treatment groups. Of 14 brain regions examined, 13 showed pooled treatment group responses in the direction of improvement by week 39, according to the company's statement.

The reduction in hippocampal neuroinflammation correlated with preservation of hippocampal volume and clinical outcomes. The placebo group showed rising free water, representing continued disease progression, while inflammation was stabilized with laromestrocel treatment.

Laromestrocel is a bone marrow-derived mesenchymal stem cell therapy that has received Regenerative Medicine Advanced Therapy designation and Fast Track designation from the FDA for mild Alzheimer's disease treatment.

The Miami-based clinical stage biotechnology company is developing laromestrocel for three pipeline indications: hypoplastic left heart syndrome, Alzheimer's disease, and pediatric dilated cardiomyopathy.

You May Also Be Interested In